Regeneron Pharmaceuticals Cancels Suffern Project; Plans to Sell Storied Former Avon Property
“The decision reflects the progress of our Tarrytown project, which is providing additional lab and office space to meet the needs of our growing R&D pipeline, as well as our desire to keep more colleagues together on fewer campuses.”